← Back to Search

Incremental vs Conventional Hemodialysis for Kidney Failure

N/A
Recruiting
Led By Andrea Viecelli, Dr
Research Sponsored by The University of Queensland
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Commencing HD as their initial dialysis therapy
Adults (≥ 18 years of age)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3, 6, 9, 12, 15 and 18 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if dialysis is a safe, practical, and cost-effective way to improve quality of life for dialysis patients and families.

Who is the study for?
The INCH-HD trial is for adults over 18 who are starting hemodialysis (HD) as their first treatment for kidney failure. They must be able to consent to the study and likely stay on HD for at least a year. People with urine output less than half a liter per day can't join.
What is being tested?
This trial compares incremental HD, which gradually increases dialysis frequency, with conventional HD that uses a regular schedule from the start. It aims to see if incremental HD better maintains quality of life and is safe and cost-effective.
What are the potential side effects?
While specific side effects aren't listed here, typical risks associated with hemodialysis may include low blood pressure, muscle cramps, itching, sleep problems, anemia, bone diseases, high blood potassium levels or infection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am starting hemodialysis as my first dialysis treatment.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3, 6, 9, 12, 15 and 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3, 6, 9, 12, 15 and 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Heath related quality of life
Secondary study objectives
Adverse events and side-effects
Fatigue
Healthcare costs
+13 more
Other study objectives
Patient lifestyle and wellbeing
Time to event

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Incremental HDExperimental Treatment1 Intervention
Participants randomised to incremental HD will commence HD twice weekly and continue until an indication for an increase to three sessions/week (trigger point) is reached.
Group II: Conventional HDExperimental Treatment1 Intervention
Participants randomised to conventional HD will commence HD thrice weekly from the first HD session.

Find a Location

Who is running the clinical trial?

The University of QueenslandLead Sponsor
144 Previous Clinical Trials
69,801 Total Patients Enrolled
Medical Research Future FundOTHER
8 Previous Clinical Trials
209,746 Total Patients Enrolled
Queensland HealthOTHER_GOV
4 Previous Clinical Trials
18,516 Total Patients Enrolled

Media Library

Conventional HD Clinical Trial Eligibility Overview. Trial Name: NCT04932148 — N/A
Renal Failure Research Study Groups: Incremental HD, Conventional HD
Renal Failure Clinical Trial 2023: Conventional HD Highlights & Side Effects. Trial Name: NCT04932148 — N/A
Conventional HD 2023 Treatment Timeline for Medical Study. Trial Name: NCT04932148 — N/A
~155 spots leftby Aug 2026